Broadcasts.com - browse "Science" podcasts

Published: Jan. 29, 2024, 5 a.m.
Duration: 9 minutes 50 seconds In these results, they found no evidence for associations between numbers of asymptomatic adverse events at any grade and side-effect bother. On the other hand, they found strong evidence for associations with symptomatic adverse events of grade 2 and 3 or higher both for side-effect bother as an outcome and with treatment discontinuation. Asymptomatic grade 2 adverse events were associated with treatment discontinuation but not side-effect bother, and symptomatic grade 1 adverse events were associated with side-effect bother but not treatment discontinuation.\\xa0

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 The authors conclude that adverse events of all grades, especially symptomatic adverse events, should be recorded regularly in cancer clinical trials. Formal patient reported outcomes are not typically collected as frequently as adverse events are recorded, so identifying patients with a high number of lower grade adverse events could be used to facilitate early supportive care to improve patient quality of life and reduce the likelihood for treatment discontinuation.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 They also highlight their result identifying lower odds of treatment discontinuation with larger numbers of grade 1 adverse events. They provide one explanation that patients may perceive grade 1 adverse events being associated with treatment efficacy, but this perception changes with higher grades.\\xa0 In their call to collect more lower grade adverse events, the authors acknowledge that recording more adverse events may be time-consuming and burdensome for sites and recommend cost-benefit analyses to develop future guidelines.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 This balance between the benefits and costs of increased adverse event data collection is the focus of Dr. Neuman\\u2019s editorial. Dr. Neuman acknowledges that Dr. O\\u2019Connell\\u2019s article provides a convincing argument for how low grade adverse event information is valuable, but notes the clinical trial context that current efforts at the NCI are to more efficiently conduct cancer research, which could be supported by streamlining data collection.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 Requiring the collection of low grade adverse events could have important impacts to trial logistics. Due to the high volume of low grade adverse events, reporting all low grade events could delay reporting higher grade and more serious adverse events; and it would require an increase in the effort of clinical trial research staff, which would be difficult if not accompanied by an increase in reimbursement to sites.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 Dr. Neuman suggests 3 approaches to balance the costs and benefits of collecting low and moderate grade adverse events. First, investigators could consider limiting low-grade adverse event reporting to the experimental arm. The standard of care regimens may not always have low-grade adverse event data available, but this may still be justified when there is extensive clinical experience with the standard of care. However, this approach is only practical when the experimental arm is not blinded.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 A second approach for moderating the effort in collecting low-grade adverse events is to limit collection to symptomatic adverse events, connecting with Dr. O\\u2019Connell\\u2019s example E1912 dataset. This approach could be addressed by prespecifying types of symptomatic adverse events that would be most impactful during the trial design phase.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 Dr. Neuman\\u2019s third suggestion is to plan for a follow-up study after the phase 3 trial to collect low-grade adverse event data and their impact on patients\\u2019 experiences and treatment discontinuation. This would be beneficial by only requiring low-grade adverse events in an experimental regimen that has successfully passed phase 3. However, a new study would require funding and site enthusiasm, which could prove challenging.

\\xb7\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0 Overall, Dr. Neuman emphasizes that investigators should develop trial-specific considerations and engage with the relevant stakeholders during study design. Because of the complexity of adverse events in these patient populations, the best uses of grade 1-2 adverse events will likely continue to develop in the future. In their article, Dr. O\\u2019Connell\\u2019s team studied grade 1 and 2 adverse events as separate predictors, but I would be curious to know how the accumulation and trajectory of these adverse events affect the patient experience. For example, even if the severity does not rise to grade 3, an increasing trend in a patient\\u2019s adverse event severities could signal the treating physician to modify study dose or to discontinue the treatment. I\\u2019m not sure if that type of information was available in their trial E1912, but perhaps that could be a factor to consider for the future. And, of course, it will be important to assess how these grade 1-2 adverse events relate to the patient experience in different studies, especially across different cancer patient populations, acknowledging that this is inherently challenging to study because the data to inform this research is not universally available. As Dr. Neuman indicates, trial-specific goals and expertise will remain critical when considering the data collection for a given trial.\\xa0

That concludes this episode of JCO Article Insights regarding a summary of the article \\u201cThe Importance of Low and Moderate Grade Adverse Events on Patients\\u2019 Treatment Experience and Treatment Discontinuation\\u201d by Dr. O\\u2019Connell and colleagues and the editorial entitled \\u201cPatient Experience, Adverse Event Reporting, and Clinical Trial Design\\u201d by Dr. Neuman. This is Subodh Selukar. Thank you for your attention and stay tuned for the next episode of JCO Article Insights.

'

-->

Listed in: Science

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Published: Nov. 5, 2023, 7 p.m.
Duration: 23 minutes 23 seconds

Listed in: Science

JCO Article Insights: Safety and efficacy of a Novel ADC Targeting TROP-2 in Metastatic Non-Small Cell Lung Cancer (NSCLC)

Published: Oct. 30, 2023, 4 a.m.
Duration: 27 minutes 37 seconds

Listed in: Science

Economic Evaluation of a Non-Medical Financial Assistance Program on Missed Treatment Appointments Among Adults With Cancer

Published: Oct. 28, 2023, 11:10 a.m.
Duration: 24 minutes 24 seconds

Listed in: Science

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Original Report:\\xa0\\xa0

Find more articles from the\\xa0June\\xa01 issue

\\xa0

'

-->

Listed in: Science

Sequencing Matters Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq Trial

Published: March 9, 2023, 5 a.m.
Duration: 26 minutes 52 seconds

Listed in: Science

How to Confront Climate Change: A Framework for Change in the Operating Room and Hospital as a Whole. A Conversation with Dr. Anaeze Offodile and Dr. Elizabeth Yates

Published: June 17, 2022, 4 a.m.
Duration: 27 minutes 51 seconds

Listed in: Science

Subspecialty Palliative Care Involvement May Lessen the Need for High-Intensity End-of-Life Care for Adolescents and Young Adults With Cancer

Published: Aug. 1, 2021, 4 a.m.
Duration: 9 minutes 50 seconds

Listed in: Science

Can the Incorporation of Minimal Residual Disease Detection Enhance Post-CAR T Outcomes in Patients With Large B-Cell Lymphoma?

Published: July 10, 2021, 4 a.m.
Duration: 6 minutes 42 seconds

Listed in: Science

Microsatellite Instability as a Prognostic Marker for Resectable Gastric Cancer and a Potential Biomarker for Perioperative Chemotherapy Benefit

Published: Nov. 1, 2019, 4 a.m.
Duration: 7 minutes 11 seconds

Listed in: Science

How Low Can You Go? Impact of Baseline Corticosteroid Use on Immunotherapy Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer

Published: Aug. 20, 2018, 8 p.m.
Duration: 8 minutes 56 seconds

Listed in: Science

Expanding Treatment Options for Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Published: Aug. 14, 2018, 8 p.m.
Duration: 8 minutes 14 seconds

Listed in: Science

The Addition of Another Camptothecin Fails to Improve Outcomes in Patients With Intermediate-Risk Rhabdomyosarcoma

Published: Aug. 9, 2018, 8 p.m.
Duration: 10 minutes 56 seconds

Listed in: Science

The Addition of IKZF1 Deletion in Risk Stratification for Children with Newly Diagnosed B-Acute Lymphoblastic Leukemia Leads to Improved Survival: Results of the Malaysia-Singapore ALL 2010 Study

Published: July 26, 2018, 5 p.m.
Duration: 7 minutes 32 seconds

Listed in: Science

Psychosocial Outcomes Following Contralateral Prophylactic Mastectomy: Insights and Opportunities

Published: July 25, 2018, 8 p.m.
Duration: 8 minutes 11 seconds

Listed in: Science

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

Published: June 18, 2018, 5:17 p.m.
Duration: 8 minutes 40 seconds

Listed in: Science

Don't Treat Me Like a Child: The Intensification of Conventional Chemotherapy in Adults With Acute Lymphoblastic Leukemia

Published: June 4, 2018, 7:56 p.m.
Duration: 9 minutes 22 seconds

Listed in: Science

An International Phase II Trial of Single-Agent Nivolumab for Hodgkin Lymphoma Relapsed or Refractory After Autologous Stem Cell Transplant

Published: March 27, 2018, 8 p.m.
Duration: 10 minutes 52 seconds

Listed in: Science

Understanding the 'Value-Added' by Specialized Pediatric Palliative Care Teams in the Care of Children With Cancer at the End of Life

Published: Jan. 22, 2018, 9 p.m.
Duration: 11 minutes 42 seconds

Listed in: Science

Survival Following Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Early-Stage Hepatocellular Carcinoma

Published: Jan. 12, 2018, 9 p.m.
Duration: 8 minutes 43 seconds

Listed in: Science

The True Costs of the 21-Gene Assay in a Cohort of 1,000 Patients

Published: Dec. 1, 2017, 9 p.m.
Duration: 6 minutes 41 seconds

Listed in: Science

Persistent Use of Opioids After Cancer Surgery

Published: Oct. 19, 2017, 8 p.m.
Duration: 7 minutes 24 seconds

Listed in: Science

Discussion on the CostEffectiveness Analysis of the CALGB/Alliance Trial and the Use of Zoledronic Acid Generic in Women With Metastatic Breast Cancer

Published: Oct. 12, 2017, 8 p.m.
Duration: 8 minutes 13 seconds

Listed in: Science

Low-Income Subsidy and Financial Barrier to Access Costly Oral Chemotherapy Drugs for Myeloma Patients Enrolled in Medicare Part D

Published: June 8, 2017, 8:30 p.m.
Duration: 10 minutes 23 seconds

Listed in: Science

Intensification of Consolidation Therapy for Acute Myeloid Leukemia by the Addition of Clofarabine to Cytarabine Improves Relapse-Free Survival

Published: Feb. 21, 2017, 9 p.m.
Duration: 11 minutes 12 seconds

Listed in: Science

Watching Nivolumabs Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

Published: Nov. 14, 2016, 9 p.m.
Duration: 7 minutes 58 seconds

Listed in: Science

Getting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac Dysfunction

Published: Oct. 26, 2016, 8 p.m.
Duration: 11 minutes 13 seconds

Listed in: Science

Listen to Your Patients

Published: Oct. 3, 2016, 8 p.m.
Duration: 12 minutes 58 seconds

Listed in: Science

Impact of Organizational Characteristics and Process of Care on Hospital Mortality and Resource Use in Cancer Patients Admitted to Intensive Care Units

Published: Sept. 13, 2016, 2 a.m.
Duration: 9 minutes 37 seconds

Listed in: Science

Restrictions on Nutrition, Social Contacts, and Pets Are Not Effective Anti-Infective Measures in Children With Acute Myeloid Leukemia

Published: June 6, 2016, 8 p.m.
Duration: 10 minutes 6 seconds

Listed in: Science

Current Status of Supplemental Screening in Dense Breasts

Published: May 23, 2016, 8 p.m.
Duration: 12 minutes 23 seconds

Listed in: Science

Selective Internal Radiation Therapy for Liver-Dominant Metastatic Colorectal Cancer: Time to Put the Brakes On?

Published: May 11, 2016, 10 p.m.
Duration: 8 minutes 17 seconds

Listed in: Science

Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design

Published: May 3, 2016, 2:48 p.m.
Duration: 7 minutes 49 seconds

Listed in: Science

Web-Based Technology Can Improve Patient Understanding and Preparedness to Discuss Cancer Clinical Trials: One Step Towards a Goal of Increased Enrollment

Published: March 11, 2016, 8:25 p.m.
Duration: 9 minutes 20 seconds

Listed in: Science

Hard to RECIST: Updating and Simplifying Primary Tumor Response Guidelines for the Revised International Neuroblastoma Response Criteria (INRC)

Published: Jan. 11, 2016, 9 p.m.
Duration: 9 minutes 32 seconds

Listed in: Science

Using the CLIC Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome to Guide Treatment And Clinical Research

Published: Oct. 5, 2015, 6:20 p.m.
Duration: 8 minutes 54 seconds

Listed in: Science

Balancing Safety and Efficacy in the Treatment Hodgkin Lymphoma: Early Discontinuation of Certain Drugs Can and Should Be Done

Published: June 22, 2015, 8 p.m.
Duration: 8 minutes 35 seconds

Listed in: Science

When Toxicity and Efficacy Collide

Published: June 8, 2015, 8 p.m.
Duration: 7 minutes 29 seconds

Listed in: Science

First Results of Euramos I and Logistics of International Collaboration for Clinical Trials of Rare Diseases

Published: June 1, 2015, 8 p.m.
Duration: 8 minutes 59 seconds

Listed in: Science

Treatment Advances in Local-Regionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree that More Isnt Always Better?

Published: May 18, 2015, 8 p.m.
Duration: 11 minutes 21 seconds

Listed in: Science

Hematopoietic Stem Cell Transplant for Children With Acute Lymphoblastic Leukemia at BFM Centers: Comparable Results With Matched Sibling Donors and Matched Unrelated Donors

Published: March 19, 2015, 9:15 p.m.
Duration: 11 minutes 2 seconds

Listed in: Science

Intensified Frontline Chemoimmunotherapy with R-ACVBP May Improve Outcomes for Younger Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Published: Nov. 25, 2014, 8:52 p.m.
Duration: 7 minutes 27 seconds

Listed in: Science

Significant Dose Effect of Radiotherapy to the Pancreas and Risk of Diabetes Mellitus in Long-Term Hodgkin Lymphoma Survivors

Published: Aug. 26, 2014, 7:53 p.m.
Duration: 8 minutes 59 seconds

Listed in: Science

The End of Rituximab Maintenance for Low Tumor Burden Follicular Lymphoma

Published: Aug. 26, 2014, 7:52 p.m.
Duration: 12 minutes 38 seconds

Listed in: Science

Use of Mutational Analysis to Help Decide Whether Patients with Myelodsysplastic Syndromes Should Receive Allogeneic Hematopoietic Cell Transplant

Published: Aug. 26, 2014, 7:51 p.m.
Duration: 10 minutes 51 seconds

Listed in: Science

Why are Fellows' Burnout Rates as High as Those of Practicing Oncologists?

Published: July 21, 2014, 9:10 p.m.
Duration: 8 minutes 38 seconds

Listed in: Science

Surprisingly Good Results in BCR-ABL1-like Pediatric Acute Lymphoblastic Leukemia: What Do They Mean?

Published: July 21, 2014, 9:09 p.m.
Duration: 9 minutes 4 seconds

Listed in: Science

Should Corticosteroids Be Used for the Treatment of Pain, Fatigue and Loss of Appetite in Cancer Patients Receiving Opioids?

Published: July 7, 2014, 9:28 p.m.
Duration: 10 minutes 28 seconds

Listed in: Science

Breast Reconstructions: Inequities in Access Affecting Choice and Quality

Published: July 3, 2014, 9:30 p.m.
Duration: 11 minutes 11 seconds

Listed in: Science

Recurrent/Metastatic Human Papillomavirus-Associated Oropharynx Cancer: What Happens When This Good Prognostic Cancer Misbehaves?

Published: June 23, 2014, 3:06 p.m.
Duration: 13 minutes 9 seconds

Listed in: Science

Delayed Diagnostic Lumbar Puncture to Optimize Central-Nervous-System-Directed Therapy in Childhood Acute Lymphoblastic Leukemia

Published: May 12, 2014, 7:47 p.m.
Duration: 8 minutes 55 seconds

Listed in: Science

Capecitabine Versus Continuous Infusion 5-FU for Rectal Cancer Neoadjuvant Chemoradiation: Equivalent Effectiveness Raises Real-World Questions About Efficacy, Adherence and Economic Implications

Published: May 5, 2014, 3:37 p.m.
Duration: 13 minutes 12 seconds

Listed in: Science

Risk-Reducing Oophorectomy in Women with BRCA1 and BRCA2 Mutations: An Opportunity to Personalize Recommendations for Cancer Prevention

Published: March 31, 2014, 9:26 p.m.
Duration: 9 minutes 21 seconds

Listed in: Science

Anti-EGFR Monoclonal Antibodies in the First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The PEAK Experience

Published: March 31, 2014, 9:25 p.m.
Duration: 8 minutes 38 seconds

Listed in: Science

Accuracy of BRCAPRO in Women with Ovarian Cancer

Published: March 17, 2014, 7:37 p.m.
Duration: 12 minutes 30 seconds

Listed in: Science

Serious Bevacizumab-Associated Gastrointestinal Toxicity

Published: March 17, 2014, 7:35 p.m.
Duration: 8 minutes 33 seconds

Listed in: Science

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes

Published: March 17, 2014, 7:34 p.m.
Duration: 10 minutes 18 seconds

Listed in: Science

Benefits of Modified Craniospinal Radiation Therapy for Children Treated for Medulloblastoma: Preserving Long-Term Neurocognitive Function

Published: Feb. 10, 2014, 7:05 p.m.
Duration: 8 minutes 22 seconds

Listed in: Science

HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers

Published: April 15, 2013, 6:42 p.m.
Duration: 10 minutes 33 seconds

Listed in: Science

Immunohistochemical Double Hit Score in Diffuse Large B-Cell Lymphoma: The Potential to Screen All Tumors for High-Risk Biology

Published: Sept. 4, 2012, 7:33 p.m.
Duration: 11 minutes 9 seconds

Listed in: Science

The German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow Up of 11 Years: Implications of Long Term Follow Up

Published: April 23, 2012, 7:45 p.m.
Duration: 8 minutes 10 seconds

Listed in: Science

Carboplatin-Gemcitabine-Bevacizumab: Expanding Treatment Options for Recurrent Platinum Sensitive Epithelial Ovarian Cancer

Published: April 23, 2012, 7:45 p.m.
Duration: 12 minutes 29 seconds

Listed in: Science

Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities

Published: Feb. 28, 2012, 7:12 p.m.
Duration: 10 minutes 38 seconds

Listed in: Science

Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers?

Published: Feb. 28, 2012, 7:09 p.m.
Duration: 10 minutes 40 seconds

Listed in: Science

Recurrence and Survival Results of the GOG Lap2 Trial Confirm Safety of the Laparoscopic Approach to Surgical Staging and Treatment for Uterine Cancer

Published: Jan. 30, 2012, 6:26 p.m.
Duration: 10 minutes 22 seconds

Listed in: Science

Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib

Published: Jan. 9, 2012, 3:12 p.m.
Duration: 8 minutes 55 seconds

Listed in: Science

Combinations or Single Agents, Crossover or No Crossover: Considering Chemotherapy Strategies in the Multi-Chaptered Story of Metastatic Breast Cancer

Published: Nov. 14, 2011, 5:22 p.m.
Duration: 8 minutes 47 seconds

Listed in: Science

Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-Carriers: A Single Institution Experience

Published: Aug. 31, 2011, 6:30 p.m.
Duration: 12 minutes 17 seconds

Listed in: Science

Vaccination with an Autologous Idiotype Based Vaccine Following a Chemotherapy Induced Remission Holds Promise in the Treatment of Patients with Follicular Lymphoma

Published: May 31, 2011, 1:48 p.m.
Duration: 12 minutes 29 seconds

Listed in: Science

Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer

Published: May 23, 2011, 3:17 p.m.
Duration: 12 minutes 40 seconds

Listed in: Science

Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients

Published: March 17, 2011, 6:36 p.m.
Duration: 11 minutes 6 seconds

Listed in: Science

RIBBON-1 Revisited

Published: March 17, 2011, 6:36 p.m.
Duration: 8 minutes 41 seconds

Listed in: Science

Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Delay Skeletal Events in Patients With Solid Tumors and Multiple Myeloma

Published: March 17, 2011, 6:36 p.m.
Duration: 8 minutes 11 seconds

Listed in: Science